ADHD medication and your genes study
Part of Mental health clinical trials.
This study looks at how your genes affect your response to Methylphenidate (a common ADHD medication, excluding the quick-release forms). If you live in Western Canada and are starting this treatment, your participation could help doctors personalize ADHD care in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 6 and 24 years old.
- You live in Western Canada (Alberta, British Columbia, Saskatchewan, or Manitoba).
- You have a diagnosis of ADHD (any type).
- You are about to start treatment with Methylphenidate (but not the immediate-release form).
- You do not have certain other conditions like psychosis, bipolar disorder, eating disorder, autism, or Tourette's.
- You have not had a liver or bone marrow transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests starting a new medication (Methylphenidate or Guanfacine) in young children with moderate or severe ADHD to see how well it works and if it’s safe.
This study looks at how the brain's electrical activity may predict whether a child with ADHD will respond well to methylphenidate (Ritalin). It aims to find biological markers that could help doctors choose the right treatment sooner.
This study tests whether brain wave recordings (EEG) can help predict how well children with ADHD will respond to stimulant medications. It aims to find the best treatment faster, potentially reducing the guesswork in choosing the right medication.
This Phase 4 study checks whether certain markers change in the brain/body when children with ADHD take methylphenidate (a stimulant). It also compares these markers with healthy children to better understand ADHD.
This study looks at whether the medication methylphenidate (often used for ADHD) can help people who have both ADHD and an addiction. It aims to see if the medicine is safe and works well for people with both conditions.
This study tests if the medication methylphenidate (commonly used for ADHD) can help manage attention and behavior problems in people with KBG syndrome. Each person acts as their own test case to see if the drug works for them.
Hear when a new Attention-Deficit/ Hyperactivity Disorder (ADHD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.